
Kardigan Inc (KARD) Stock Forecast & Price Target
Kardigan Inc (KARD) Analyst Ratings
Bulls say
Kardigan is attractive fundamentally because it owns three late-stage cardiovascular programs aimed at large, underserved indications with no disease-modifying therapies, and each asset has prior human data that de-risks the pipeline. Danicamtiv has shown coherent improvements in LVEF, LVGLS, and LAFI in genetic DCM, ataciguat previously reduced aortic valve calcium progression by about 70% versus placebo in CAVS, and tonlamarsen achieved a 67% AGT reduction with favorable safety in ASH-related development work. Its roughly $591 million cash position should fund all three Phase 2b programs through topline readouts into Phase 3, while Prolaio’s over four million hours of physiologic data adds an additional, potentially differentiated trial-design advantage.
Bears say
Kardigan is viewed negatively because its lead tonlamarsen program missed the BP co-primary in KARDINAL, with both groups showing identical 6.7 mmHg office systolic BP reductions at Week 20 and only descriptive secondary findings, undermining confidence that greater AGT suppression adds meaningful clinical benefit. The active run-in design and absence of a true placebo-only arm cloud interpretation, but the fact that this remains the highest-risk program is compounded by the novelty of the ASH transition-of-care market, which has no approved therapies and unproven commercial adoption. Financially, Kardigan is still pre-revenue, reported about $661M cash as of 2Q26, and expects runway into 2028, yet it likely needs substantial additional funding while facing regulatory, competitive, and clinical development risk across all three Phase 2b assets.
This aggregate rating is based on analysts' research of Kardigan Inc and is not a guaranteed prediction by Public.com or investment advice.
Kardigan Inc (KARD) Analyst Forecast & Price Prediction
Start investing in Kardigan Inc (KARD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kardigan Inc (KARD) Forecast
Kardigan Inc (KARD) Analyst Forecast & Price Prediction
Start investing in Kardigan Inc (KARD)
Order type
Buy in
Order amount
Est. shares
0 shares